{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.03","value":"7.1"},{"groupId":"OG001","spread":"1.65","value":"7.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"210"},{"groupId":"OG001","value":"102"}],"units":"Participants"}],"title":"Week 1 - 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.02","value":"7.0"},{"groupId":"OG001","spread":"1.61","value":"7.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"201"},{"groupId":"OG001","value":"96"}],"units":"Participants"}],"title":"Week 25 - 48"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.04","value":"7.0"},{"groupId":"OG001","spread":"1.28","value":"7.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"title":"Week 49 - 72"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.13","value":"7.0"},{"groupId":"OG001","spread":"1.00","value":"7.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"155"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Week 73 - 96"}],"denoms":[{"counts":[{"groupId":"OG000","value":"210"},{"groupId":"OG001","value":"102"}],"units":"Participants"}],"description":"The number of transfusion events after start of study treatment were evaluated. For the definition of transfusion events, if multiple transfusions happen on the same date, they are counted as one event; if multiple transfusions happen on two consecutive dates, they are counted as one event; if multiple transfusions happen on three consecutive dates, they are counted as two events. Results are presented in 24-week intervals, up to 96 weeks after start of study treatment","dispersionType":"Standard Deviation","groups":[{"description":"Luspatercept (ACE-536) was administered subcutaneously (SC) at a starting dose level of 1 mg/kg once every 21 days. Participants could be dose-titrated to 1.25 mg/kg, but the maximum total dose should not exceed 120 mg, total dose per administration during the Treatment Period, the Long-term Treatment Period, and Open-Label Treatment Period. BSC = Best Supportive Care","id":"OG000","title":"Luspatercept + BSC"},{"description":"Placebo (normal saline) was administered subcutaneously (SC) in volumes to match active treatment once every 21 days. BSC = Best Supportive Care","id":"OG001","title":"Placebo + BSC"}],"paramType":"MEAN","populationDescription":"All randomized participants who received transfusions","reportingStatus":"POSTED","timeFrame":"From first dose through 3 weeks post last dose (up to approximately 218 weeks)","title":"Post-Baseline Transfusion Event Frequency","type":"SECONDARY","unitOfMeasure":"Number of transfusions"}